Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2025)

Allogene Therapeutics has reported Receivables - Other for 4 years, with the latest figure at $1.2 million in Q1 2023.

• Quarterly Receivables - Other fell 87.23% year-over-year to $1.2 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $1.2 million (down 87.23% YoY) and the FY2022 annual result came in at $1.5 million, down 63.41% from the prior year.
• Receivables - Other eased to $1.2 million in Q1 2023 per ALLO's latest filing, from $1.5 million in the prior quarter.
• Over five years, Receivables - Other peaked at $10.2 million in Q2 2022 and troughed at $1.2 million in Q1 2023.
• A 4-year average of $5.2 million and a median of $4.2 million in 2021 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other soared 142.86% in 2022, then slumped 87.23% in 2023.
• Over 4 years, Receivables - Other stood at $3.8 million in 2020, then advanced by 7.89% to $4.1 million in 2021, then slumped by 63.41% to $1.5 million in 2022, then slipped by 20.0% to $1.2 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.2 million, $1.5 million, and $4.3 million for Q1 2023, Q4 2022, and Q3 2022 respectively.